menu
    • menu
    [{"orgOrder":0,"company":"Healthpoint","sponsor":"Healthpoint","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Bacitracin Zinc","moa":"C55-isoprenyl pyrophosphate","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthpoint \/ Healthpoint","highestDevelopmentStatusID":"11","companyTruncated":"Healthpoint \/ Healthpoint"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Podiatry","graph2":"Phase IV","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Podiatry","graph2":"Phase IV","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Enzyme","year":"2012","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Healthpoint","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Healthpoint \/ Healthpoint","highestDevelopmentStatusID":"1","companyTruncated":"Healthpoint \/ Healthpoint"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Podiatry","graph2":"Phase IV","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Podiatry","graph2":"Phase IV","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Podiatry","graph2":"Phase IV","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"UNITED KINGDOM","productType":"Enzyme","year":"2011","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Podiatry","graph2":"Phase IV","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"SMITH & NEPHEW INC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"HP802-247","moa":"Keratinocyte\/Fibroblast","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Healthpoint \/ SMITH & NEPHEW INC","highestDevelopmentStatusID":"10","companyTruncated":"Healthpoint \/ SMITH & NEPHEW INC"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"HP802-247","moa":"Keratinocyte\/Fibroblast","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"HP802-247","moa":"Keratinocyte\/Fibroblast","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"HP802-247","moa":"Keratinocyte\/Fibroblast","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"HP802-247","moa":"Keratinocyte\/Fibroblast","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"HP802-247","moa":"Keratinocyte\/Fibroblast","graph1":"Oncology","graph2":"Phase II","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"HP802-247","moa":"Keratinocyte\/Fibroblast","graph1":"Undisclosed","graph2":"Phase I","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Balsam Peru","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Fibrin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"HP011-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"HP828-101","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Healthpoint \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Healthpoint

    Menu

    Healthpoint

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HP802-247

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers

                            Details : HP802-247 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leg Ulcer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 03, 2014

                            Lead Product(s) : HP802-247

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Inhibitor

                            Therapeutic Area : Podiatry

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Santyl Applications to Diabetic Foot Ulcers

                            Details : Collagenase is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            April 11, 2014

                            Lead Product(s) : Collagenase Inhibitor

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HP802-247

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers

                            Details : HP802-247 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Varicose Ulcer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 15, 2013

                            Lead Product(s) : HP802-247

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HP802-247

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ââ€...

                            Details : HP802-247 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Leg Ulcer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 30, 2012

                            Lead Product(s) : HP802-247

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bacitracin Zinc

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase IV

                            Recipient : University of Louisville

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Wound Bed Establishment in Facial Burns

                            Details : Bacitracin is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Burns.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 17, 2012

                            Lead Product(s) : Bacitracin Zinc

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase IV

                            Recipient : University of Louisville

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HP802-247

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : SMITH & NEPHEW INC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers

                            Details : HP802-247 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Leg Ulcer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 03, 2012

                            Lead Product(s) : HP802-247

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : SMITH & NEPHEW INC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HP802-247

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa

                            Details : HP802-247 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Epidermolysis Bullosa Dystrophica.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 08, 2012

                            Lead Product(s) : HP802-247

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Inhibitor

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Using Santyl or Bacitracin on Second Degree Burns

                            Details : Collagenase is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Burns.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            January 24, 2012

                            Lead Product(s) : Collagenase Inhibitor

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Balsam Peru

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury

                            Details : Balsam Peru is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pressure Ulcer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 13, 2011

                            Lead Product(s) : Balsam Peru

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Healthpoint

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Inhibitor

                            Therapeutic Area : Podiatry

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Using Santyl on Diabetic Foot Ulcers

                            Details : Santyl is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetic Foot.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            August 03, 2011

                            Lead Product(s) : Collagenase Inhibitor

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth